Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26497743 | 0.92 | GAA (0.41) | F13A1TGM2TGM1CYP3A4HSD11B1 | |
| SCHEMBL30592035 | 0.84 | TRPV1 (0.44) | CYP3A4HSD11B1GAATRPV1TRPA1 | |
| SCHEMBL26107616 | 0.82 | HSD11B1 (0.41) | F13A1TGM2TGM1CYP3A4HSD11B1 | |
| SCHEMBL26106788 | 0.82 | HSD11B1 (0.41) | F13A1TGM2TGM1CYP3A4HSD11B1 | |
| SCHEMBL30591832 | 0.81 | EPHX2 (0.52) | CYP3A4HSD11B1TRPV1 | |
| SCHEMBL31474447 | 0.79 | RBP4 (0.46) | F13A1TGM2TGM1HSD11B1GAA | |
| SCHEMBL26105982 | 0.78 | HSD11B1 (0.44) | F13A1TGM2TGM1CYP3A4HSD11B1 | |
| SCHEMBL30591753 | 0.78 | HSD11B1 (0.44) | F13A1TGM2TGM1CYP3A4HSD11B1 | |
| SCHEMBL31474450 | 0.75 | KIT (0.39) | F13A1TGM2TGM1HSD11B1GAA | |
| SCHEMBL30591869 | 0.73 | HTR1A (0.41) | F13A1TGM2TGM1CYP3A4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | claimed |
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | claimed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | claimed |
| WO-2023183768-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-28 | — | — | WO | claimed |
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE | 2025-06-26 | — | — | US | disclosed |
| CN-119403551-A | Small molecule inhibitors of TEA domain family members | 斯克里普斯研究学院 | 2025-02-07 | — | — | CN | disclosed |
| EP-4496570-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | The Scripps Research Institute (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023183768-A2 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206722-A1 | SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS | YAP1, TEAD1, TEAD2 | F13A1 3351/4885TGM2 1913/4885TGM1 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.